



HAL
open science

Hantavirus-specific IgA in saliva and viral antigen in the parotid gland in patients with hemorrhagic fever with renal syndrome

Lisa Pettersson, Johan Rasmuson, Charlotta Andersson, Clas Ahlm, Magnus Evander

► To cite this version:

Lisa Pettersson, Johan Rasmuson, Charlotta Andersson, Clas Ahlm, Magnus Evander. Hantavirus-specific IgA in saliva and viral antigen in the parotid gland in patients with hemorrhagic fever with renal syndrome. *Journal of Medical Virology*, 2011, 83 (5), pp.864. 10.1002/jmv.22040 . hal-00616896

HAL Id: hal-00616896

<https://hal.science/hal-00616896>

Submitted on 25 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Hantavirus-specific IgA in saliva and viral antigen in the parotid gland in patients with hemorrhagic fever with renal syndrome

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-2157.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	22-Dec-2010
Complete List of Authors:	Pettersson, Lisa; Umeå University, Clinical Microbiology/Division of Virology Rasmuson, Johan; Umeå University, Clinical Microbiology/Division of Infectious diseases Andersson, Charlotta; Umeå University, Medical Biosciences/Division of Pathology Ahlm, Clas; Umeå University, Clinical Microbiology/Division of Infectious diseases Evander, Magnus; Umeå University, Clinical Microbiology/Division of Virology
Keywords:	Puumalavirus , HFRS, antibody, zoonosis, transmission

SCHOLARONE™
Manuscripts

1
2
3 1 **Hantavirus-specific IgA in saliva and viral antigen in the parotid gland in patients with**
4
5
6 2 **haemorrhagic fever with renal syndrome**
7
8
9 3

10
11
12 4 Lisa Pettersson¹, Johan Rasmuson², Charlotta Andersson³, Clas Ahlm² and Magnus Evander^{1*}
13
14
15

16 5

17
18
19 6 ¹Department of Clinical Microbiology, Virology, ² Department of Clinical Microbiology,
20
21
22 7 Infectious Diseases, ³Department of Medical Biosciences, Pathology, Umeå University,
23
24 8 Umeå, Sweden.
25
26

27 9

28
29
30
31 10 *Corresponding author: Magnus Evander, Department of Clinical Microbiology, Virology,
32
33 11 Umeå University, S-901 85, Umeå, Sweden.
34
35

36
37 12 Phone: +46-90-7851790. Fax: +46-90-129905. E-mail: magnus.evander@climi.umu.se.
38
39
40 13

41
42
43 14 Running head: Hantavirus IgA in human saliva
44
45
46
47 15
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 **ABSTRACT**
4
5

6 2 The *Hantavirus* genus comprises rodent borne, zoonotic viruses of the *Bunyaviridae* family
7
8 3 that cause haemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus
9
10 4 cardiopulmonary syndrome (HCPS) in the Americas. Rodent saliva contains infectious
11
12 5 hantavirus and evidence suggests that hantavirus is also shed in human saliva, but person-
13
14 6 to-person transmission is rare. In saliva, immunoglobulin (Ig) A is the predominant
15
16 7 immunoglobulin class. Secretory IgA serves as an important first line of defence on epithelial
17
18 8 surfaces and the binding of secretory IgA to pathogens can inhibit adherence of
19
20 9 microorganisms to mucosal cells and neutralize viruses. This study investigated the presence
21
22 10 and importance of salivary IgA in relation to viral antigen in the saliva by testing Puumala
23
24 11 hantavirus (PUUV) specific IgA, RNA, and antigen in saliva in acutely ill patients with HFRS. In
25
26 12 saliva samples, PUUV specific IgA was detected in twelve of 33 (36%) patients with HFRS and
27
28 13 twenty (61%) were PUUV RNA positive. There was a statistically significant inverse
29
30 14 association between the presence of salivary IgA antibodies and PUUV RNA in the saliva.
31
32 15 PUUV-specific IgA in saliva was not found in a long term follow-up, while PUUV IgA in serum
33
34 16 was detected in three patients, 28-32 months after the initial study. Notably, both PUUV
35
36 17 RNA and PUUV nucleocapsid antigen were detected in endothelial cells within the parotid
37
38 18 gland of a deceased patient with HFRS.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22 Keywords: Puumalavirus, HFRS, HCPS, antibody, zoonosis, transmission

1 INTRODUCTION

2 Viruses in the *Hantavirus* genus are rodent borne, zoonotic viruses of the *Bunyaviridae*
3 family and belong to the group of viral haemorrhagic fevers. Typically, hantaviruses cause
4 haemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary
5 syndrome (HCPS) in the Americas. HFRS symptoms include fever, renal failure, and
6 hemorraghia and HCPS symptoms include fever and severe pulmonary oedema; however,
7 between 10-30% of HFRS patients caused by *Puumala virus* (PUUV) (genus *Hantavirus* and
8 family *Bunyaviridae*) also display symptoms in the lower respiratory tract [Kanerva et al.,
9 1996; Linderholm et al., 1993; Linderholm et al., 1997]. The hantaviruses are negative
10 stranded RNA- viruses consisting of spherical, enveloped particles 90 to 120 nm in diameter
11 that contain two glycoproteins (Gn and Gc) and enclose three unique negative-stranded
12 RNAs (L, M, and S) associated with the RNA dependent RNA polymerase and the
13 nucleocapsid protein.

14
15 Typically, hantavirus infection is the result of inhalation of aerosol containing virus shed in
16 rodent excreta (saliva, urine, and faeces). However, in South America several person-to-
17 person transmissions with *Andes virus* (ANDV) have been noted; the highest risk of
18 contracting hantavirus by person-to-person transmission is attributed to very close contact
19 (sexual relations or intimate kissing) with a person infected with a hantavirus [Ferres et al.,
20 2007; Martinez et al., 2005]. In a previous study, saliva from patients with HFRS was found to
21 contain PUUV RNA [Pettersson et al., 2008]. Similarly, rodent saliva contains infectious
22 hantavirus [Douron et al., 1984; Hardestam et al., 2008a; Padula et al., 2004; St Jeor, 2004].
23 These observations indicate that human saliva aerosol or droplets could be a route of

1
2
3 1 person-to-person transmission, yet human saliva from HFRS patients containing PUUV RNA
4
5
6 2 has not been shown hitherto to be infectious [Hardestam et al., 2008b]. The reported
7
8
9 3 possibility of person-to-person transmission with the highly pathogenic ANDV (case-fatality
10
11 4 rate up to 40%) raise concerns whether hantaviruses could constitute a risk for further
12
13
14 5 epidemic spread among humans. Consequently, presence of virus in saliva during infection
15
16 6 and factors that could enhance or decrease transmission are therefore of utmost interest.
17

18
19
20
21 8 Whole human saliva may inhibit the infectivity of several different viruses *in vitro* [Fox et al.,
22
23
24 9 1988; Hartshorn et al., 2006]. In the *Hantavirus* genus, human saliva inhibited propagation in
25
26 10 cell culture for PUUV and *Hantaan virus* (HTNV), while ANDV was less sensitive to the saliva
27
28
29 11 antiviral effect [Hardestam et al., 2009]. Several components of human saliva could be
30
31
32 12 responsible for this inhibition and mucin had some inhibitory effect on HTNV infection *in*
33
34 13 *vitro* [Hardestam et al., 2008b]. Furthermore, presence of hantavirus-specific salivary
35
36 14 antibodies in an infected individual could be important for protection against the disease
37
38
39 15 and transmission. In saliva, Immunoglobulin (Ig) A is the predominant immunoglobulin class:
40
41 16 it exists as polymeric IgA with a secretory component bound to the Ig molecules. This
42
43
44 17 secretory IgA has increased resistance against proteolytic degradation. Secretory IgA is
45
46 18 produced by plasma cells that are concentrated along mucous cell membrane surfaces and
47
48
49 19 the daily production of IgA is greater than that of any other Ig class. The output in most
50
51 20 secretions amounts to some 5-8g/day in adults [Russel, 2007]. In serum, IgA constitutes only
52
53
54 21 10-15% of the total amount of Ig and exists primarily as a monomer. The parotid gland IgA-
55
56 22 to-IgG ratio is about 500 times increased compared to that in serum and 83-87% of salivary
57
58
59 23 IgA in whole saliva is polymeric IgA [Brandtzaeg, 2007]. The secretory IgA serves as an
60

1
2
3 1 important first line of defence on epithelial surfaces and the binding of secretory IgA to
4
5
6 2 pathogens can inhibit adherence of microorganisms to mucosal cells and neutralize viruses.
7
8
9 3 For instance, specific parotid and salivary IgA can neutralize *Human immunodeficiency virus*
10
11 4 *type 1* (HIV-1) (family *Retroviridae*, subfamily *Orthoretrovirinae*, genus *Lentivirus*) [Devito et
12
13 5 al., 2002; Moja et al., 2000].
14
15
16 6 Only one study has described salivary IgA antibodies against hantavirus where ANDV-specific
17
18 7 IgA was detected in saliva (six patients with acute HCPS) [Padula et al., 2000]. In serum,
19
20 8 PUUV-specific IgA was shown to have a neutralizing effect against PUUV [de Carvalho
21
22 9 Nicacio et al., 2000]. The present study investigated the presence and importance of salivary
23
24 10 IgA in relation to virus in saliva by analysing PUUV-specific IgA and viral RNA in saliva in
25
26 11 acutely ill patients with HFRS. In addition, viral RNA and antigen were examined in a salivary
27
28 12 gland of a fatal case with HFRS.
29
30
31
32
33
34
35

36 MATERIALS AND METHODS

37 Patients and sample collection

38
39
40
41
42 16 In part of a prospective study of patients with HFRS, saliva, plasma, and serum samples were
43
44 17 collected from 33 consecutive patients verified by PUUV specific IgM or real-time RT-PCR at
45
46 18 the Division of Infectious Diseases at Umeå University Hospital (Umeå, Sweden). The hospital
47
48 19 is situated in the endemic area in northern Sweden. Patients were added to the study from
49
50 20 January 2007 to February 2009. The patients were 26-82 years (mean 52 years); 21 were
51
52 21 female. The sample collection was performed during the acute phase as previously described
53
54 22 [Pettersson et al., 2008] and was random with no consideration to time of day or recent
55
56 23 food intake. For some patients, additional samples were obtained later in the acute phase.
57
58
59
60

1
2
3 1 To study the long-term duration of PUUV-specific IgA, patients were invited for new
4
5
6 2 sampling in June 2010. Twelve patients agreed to participate in the follow-up and samples
7
8
9 3 were collected in the same manner as previously described. Tissue from the parotid salivary
10
11 4 gland was sampled at autopsy three days post-mortem from a patient with HFRS who died
12
13 5 five days post onset of disease.
14

15
16 6 All experiments were performed in compliance with relevant laws and institutional
17
18
19 7 guidelines and in accordance with the ethical standards of the Declaration of Helsinki. The
20
21
22 8 project was approved by the Regional Ethics Review Board in Umeå and informed consent
23
24 9 was obtained from all patients.
25

26 27 28 10 **Real-time RT-PCR**

29
30
31 11 RNA from patient saliva, plasma, or tissue was extracted using a QIAamp® Viral RNA kit
32
33 12 (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's instructions. The real-time
34
35
36 13 RT-PCR was performed as previously described [Evander et al., 2007]. Briefly, the RNA was
37
38
39 14 reverse-transcribed followed by a real-time PCR TaqMan® assay in triplets with PUUV-
40
41 15 specific primers and probe from the S-segment. Taqman® RNase P control reagents (Applied
42
43 16 Biosystems, Foster City, CA, USA) were used to determine cell numbers in tissue. The real-
44
45
46 17 time PCR was performed using an ABI Prism 7900HT Sequence Detection System 2.0
47
48 18 (Applied Biosystems).
49

50 51 52 19 **Immunofluorescence assay (IFA)**

53
54
55 20 To detect PUUV-specific IgM and IgG antibodies in serum from patients with HFRS, IFA was
56
57
58 21 performed as described previously [Evander et al., 2007]. Briefly, the samples were diluted in
59
60 22 PBS (1:16 for IgM and 1:40 for IgG) and then applied onto spot-slide wells in a moist

1
2
3 1 chamber with the local strain PUUV Umeå/hu [Johansson et al., 2004] grown in VeroE6 cells
4
5
6 2 as antigen at 37°C over night for IgM analysis and 60 minutes at 20°C for IgG analysis. For IgA
7
8
9 3 analysis, the same antigen was used to detect PUUV-specific IgA antibodies in serum and
10
11 4 saliva. The slides were incubated over night with patient saliva (diluted 1:10) and 90 minutes
12
13 5 with serum (diluted 1:10 and 1:40) at 37°C and then PUUV-specific IgA antibodies were
14
15
16 6 detected by a polyclonal rabbit anti-human IgA-FITC (F0204, DAKO A/S, Glostrup, Denmark)
17
18 7 diluted 1:40 and incubated 60 minutes at 37°C. The salivary IgA results were confirmed by
19
20
21 8 detection of PUUV-specific salivary IgA antibodies using another detecting antibody – the
22
23
24 9 anti-human IgA-FITC (diluted 1:30) (AF010.M, Binding Site Ltd, Birmingham, UK).

10 **Immunohistochemistry**

11 The parotid salivary gland was examined for presence of viral antigen using PUUV
12
13 nucleocapsid protein specific monoclonal antibody (A1C5, Progen Biotechnik GmbH,
14
15 Heidelberg, Germany). Staining was performed on formalin-fixed paraffin-embedded 4µm-
16
17 sections that were processed for immunohistochemistry using a biotin, streptavidin, and
18
19 peroxidase technique visualized with diaminobenzidine. Parotid samples from two non-
20
21 hantavirus patients were used as negative controls.

17 **Statistical analysis**

18 For statistical calculations and graphs, the SPSS software (SPSS, Inc., Chicago, USA) was used.
19
20 Associations between parameters were evaluated using the Mann-Whitney U test. P
21
22 values<0.05 were considered statistically significant.

1 RESULTS

2 PUUV-specific RNA in saliva and plasma from acute phase

3 Of the 33 patients, 20 (61%) had PUUV RNA in their saliva and 27 (82%) in their plasma
4 (Table 1). The mean value of viral copy number in PUUV RNA positive samples was 33,091
5 copies/ml in saliva and 113,460 copies/ml in plasma, with a wide range between samples
6 (Table 1). Interestingly, PUUV RNA was detected in saliva (as long as 15 days) and plasma (as
7 long as 20 days) after disease onset (Table 1). As expected, in patients where saliva and
8 plasma were collected consecutively, the RNA-levels decreased with time (Table 1).

9 In patients where plasma and saliva were collected on the same day (for patients with
10 additional samples only one sample pair was evaluated), twelve of 19 sample pairs were
11 PUUV RNA positive in both saliva and plasma, three were negative in both, four were only
12 positive in plasma, and no sample was only positive in saliva (Table 1 and Table 2). There was
13 a significant association between presence of PUUV RNA in saliva and plasma samples, and
14 the RNA levels in plasma were significantly higher in RNA positive than in RNA negative
15 saliva ($P=0.010$, Mann-Whitney U test).

16 PUUV-specific antibodies in serum from acute phase

17 PUUV-specific IgA, IgM or IgG were found in the sera from all patients at first visit. The only
18 patient with a negative IgA serum (no. 27, Table 1) was IgG and IgM positive in the serum
19 and IgA negative in the saliva. Interestingly, this patient had been sick for six days and had
20 an extremely high viral load in the serum, 1.38×10^6 copies/ml. Three patients were only
21 weakly positive for PUUV-specific IgA in serum (no. 20, 28 and 30, Table 1). Notably, the only
22 patients with negative IgM and IgG in the serum were found in this group (no. 28 and 20

1
2
3 1 respectively) and all three were IgA negative in the saliva. The sample with negative IgG (no.
4
5
6 20, Table 1) was collected only three days after disease onset and had high viral copy
7
8
9 3 number in the plasma. After two additional days, the patient was positive for IgG in serum.
10
11 4 The patient with serum negative for PUUV IgM (no. 28) was positive for PUUV RNA both in
12
13
14 5 plasma and saliva (Table 1).

6 **PUUV-specific antibodies in saliva from acute phase**

7 PUUV-specific IgA in the saliva was detected in eleven patients at the initial visit (Table 1)
8
9 and in one additional patient two days later (no. 12, Table 1). In total, twelve of 33 patients
10
11 with HFRS had salivary IgA and there was a statistically significant inverse association
12
13 ($P=0.009$, Mann-Whitney U test) between presence of salivary IgA antibodies and PUUV RNA
14
15 in the saliva samples (Fig. 1). Of the eleven patients with HFRS with salivary IgA antibodies in
16
17 their initial sample, seven were negative for PUUV RNA in the saliva (Table 1). In contrast, 16
18
19 of 20 patients with HFRS who were positive for PUUV RNA in their initial saliva sample had
20
21 no detectable PUUV-specific salivary IgA. Only five of 33 patients had both PUUV-specific IgA
22
23 and PUUV RNA in one of their saliva samples (Table 1). In two of these patients, consecutive
24
25 samples were collected. For patient 5, PUUV RNA disappeared from the saliva four days
26
27 later, while patient 12 had no detectable salivary IgA at the initial visit, but IgA was present
28
29 in the patient's saliva two and four days later concomitant with a decrease and final
30
31 disappearance of PUUV RNA in the patient's saliva (Table 1).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

20 **Long-term follow-up of PUUV-specific IgA antibodies in saliva and serum**

21 To study the long-term duration of PUUV-specific IgA, patients were invited for a follow-up
22
23 sampling between 17 months and 32 months after falling ill with HFRS. Twelve patients

1
2
3 1 agreed to give a follow-up saliva and serum sample. All subjects were negative for IgM and
4
5
6 2 positive for IgG at this time. One patient (no. 13, Table 1) was positive for PUUV IgA in the
7
8
9 3 serum 32 months after the first sample, and two patients (no. 5 and 22, Table 1) were
10
11 4 weakly positive for IgA in their serum samples after 29 months and 28 months, respectively.
12
13 5 These three patients were all negative for IgM and positive for IgG at follow-up. The
14
15
16 6 remaining patients were negative for IgA in their sera. All patients were negative for IgA in
17
18
19 7 the saliva. No PCR was performed in the follow-up samples.

8 **PUUV IgA and RNA in serum and saliva in relation to airway symptoms, treatment, and** 9 **radiological findings**

10 In addition to the typical symptoms and clinical signs of HFRS, 22 (67%) patients had
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10 In addition to the typical symptoms and clinical signs of HFRS, 22 (67%) patients had
respiratory tract symptoms. Perhaps, PUUV RNA and PUUV-specific IgA originated from the
lungs through coughing and may be more abundant in individuals where lungs and airways
are affected. Seventeen of the 22 HFRS patients with respiratory tract symptoms had
dyspnea and 13 were coughing. Eight of the patients were treated with oxygen due to low
oxygen-saturation in the blood. A chest x-ray was performed on 12 patients; nine of these
were pathological (including infiltrates and/or pleural fluid) and three were normal.
However, no statistical significant associations (Mann-Whitney U test) were found between
presence of PUUV-specific IgA or PUUV RNA in their saliva or plasma and symptoms,
treatment, and radiological findings (data not shown).

20 **Presence of PUUV antigen and RNA in a human salivary gland**

21 To further investigate whether PUUV RNA present in the saliva could originate from the
22 salivary glands, a parotid salivary gland sample from a patient with HFRS was analysed for

1
2
3 1 presence of PUUV RNA and PUUV antigen using a monoclonal antibody (A1C5) specific for
4
5
6 2 the PUUV nucleocapsid protein. Using immunohistochemistry, the PUUV nucleocapsid
7
8
9 3 antigen was detected in the capillary endothelium and within mononuclear cells (Fig. 2).
10
11 4 Using real-time RT-PCR, 19 PUUV RNA copies/10,000 cells were demonstrated in the salivary
12
13
14 5 gland sample and 18,000 PUUV RNA copies/ml in the tracheal secretions. Unfortunately, no
15
16
17 6 saliva had been collected from this patient. Parotid samples from two non-hantavirus
18
19
20 7 patients were both negative for nucleocapsid antigen (data not shown).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9 DISCUSSION

10 Can hantavirus in human saliva be infectious, and if not, why? In the studied patients with
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

14 Both PUUV RNA and nucleocapsid antigen were detected in a human parotid gland. The viral
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 et al., 2004]. Person-person transmission of ANDV has been suggested to be mediated by
2 close contact, such as having a sexual relations or engaging in intimate kissing with a person
3 infected with hantavirus [Ferres et al., 2007; Martinez et al., 2005]. One of the studies
4 suggests that the unique route of transmission of ANDV is by means of small-particle
5 infectious saliva or respiratory aerosols during the close contact between both persons
6 [Martinez et al., 2005] .For other hantaviruses, this type of transmission has not been
7 demonstrated and, except for ANDV, whole human saliva has an inhibitory effect on several
8 hantaviruses *in vitro* [Hardestam et al., 2009]. Hantavirus-specific antibodies could also play
9 a role in decreasing the possibility for transmission during an infection.

10 In the study, the presence of secretory IgA antibodies in the saliva of a patient with HFRS
11 was significantly inversely associated with the presence of PUUV RNA in saliva, suggesting
12 that the virus could be contagious before appearance of salivary IgA. Increased titers of IgG
13 antibodies in the serum of patients with HFRS coincide with the disappearance of PUUV RNA
14 in the plasma [Evander et al., 2007] and similar kinetics of the virus-antibody relationship
15 may occur in the human oral cavity. For other viruses, it has been shown that secretory IgA
16 protects against infection [Belec et al., 2003; Renegar et al., 2004]. Hantavirus-specific IgA in
17 saliva could potentially provide protection against person-to-person transmission. For HIV-1,
18 specific salivary IgA neutralises infection *in vitro* and mucosal IgA seems to be more efficient
19 than serum IgA [Moja et al., 2000], which could be explained by the polymeric structure of
20 the mucosal secretory IgA [Hocini et al., 1997]. In addition, the antibody function of
21 secretory IgA is most likely enhanced by the high level of cross-reacting activity detected in
22 human secretions [Ma et al., 1998]. Only one study has described detection of salivary IgA
23 antibodies in hantavirus disease; the study used ANDV nucleoprotein expressed in

1
2
3 1 *Escherichia coli* as antigen in an ELISA [Padula et al., 2000]. In that report, ANDV-specific
4
5
6 2 salivary IgA was detected in six patients with HCPS up to a month after onset of symptoms
7
8
9 3 [Padula et al., 2000]. Similarly, the present study found one patient with HFRS who displayed
10
11 4 IgA antibodies in the saliva 32 days after disease onset. Furthermore, PUUV RNA was
12
13 5 detected in the saliva and plasma from patients with HFRS more than two weeks after
14
15
16 6 disease onset, a finding that is also similar to previous reports on PUUV RNA in plasma
17
18 7 [Evander et al., 2007; Saksida et al., 2008]. A decreased nucleocapsid-specific serum IgA
19
20
21 8 response in convalescent and late-convalescent-phase sera has been observed in serum
22
23 9 from patients with HFRS [de Carvalho Nicacio et al., 2000; Elgh et al., 1998; Groen et al.,
24
25
26 10 1994; Meisel et al., 2006; Padula et al., 2004], a finding also similar to the present study;
27
28 11 however, serum IgA could be detected in convalescent sera for up to ten years [de Carvalho
29
30
31 12 Nicacio et al., 2000]. The possibility of boosting with hantavirus during the follow-up period
32
33 13 cannot be excluded. In the present study, samples from 12 patients with HFRS more than
34
35
36 14 two years after disease were all negative for PUUV-specific IgA in their saliva, while three
37
38
39 15 patients were still IgA positive in sera.
40
41
42 16

43
44 17 In the acute phase, all patients but one had serum IgA while the proportion of detectable IgA
45
46
47 18 in saliva was lower. PUUV-specific IgA directed both against hantavirus nucleocapsid and
48
49
50 19 glycoproteins was detected since the antigen in the IFA consisted of PUUV-infected cells. The
51
52 20 conjugate used to reveal IgA allowed recognition of all potential molecular forms of PUUV-
53
54 21 specific IgA antibodies – e.g., monomeric, dimeric, and secretory IgA – but close to 90% of
55
56
57 22 salivary IgA in whole saliva is polymeric IgA [Brandtzaeg, 2007]. In most samples, IgA was not
58
59
60 23 detectable in saliva until the PUUV-RNA was cleared, which is in contrast to serum, where

1
2
3 1 IgA was detected regardless whether PUUV-RNA was present or not. Complexes in the
4
5
6 2 saliva, including PUUV-specific IgA and PUUV particles, might cause a negative IFA result. In
7
8
9 3 the oral cavity, secretory IgA is known to exist in complex with salivary agglutinin (agglutinin
10
11 4 gp-340; [Ligtenberg et al., 2004] and mucin [Biesbrock et al., 1991; Wickstrom et al., 2000]
12
13 5 and they inhibit infection by aggregation with virus [Habte et al., 2006; Hartshorn et al.,
14
15
16 6 2006]. Further studies that optimize hantavirus IgA detection in salivary samples could
17
18 7 increase the sensitivity of IgA detection. In the present study, PUUV RNA was detected both
19
20
21 8 in saliva and plasma and virus RNA in saliva was associated with viremia in patients with
22
23 9 HFRS, indicating that analysis of oral fluid could be useful for molecular investigation during
24
25
26 10 outbreaks. Saliva is an attractive non-invasive sample for diagnostics and epidemiological
27
28 11 studies and oral fluid samples have been shown to be useful for many infectious agents such
29
30
31 12 as the early detection of HIV [Nugent et al., 2009]. Determination of specific viral nucleic
32
33 13 acids and antibodies in saliva samples makes this test even more useful for isolated
34
35
36 14 communities and it has been suggested as a sampling technique for some native populations
37
38 15 in South America who, due to cultural reasons, do not always accept venepuncture [Padula
39
40
41 16 et al., 2000]. The direct detection and identification of many viruses in saliva by PCR could
42
43
44 17 become a standard method and numerous studies on different viruses have been reported
45
46 18 [Corstjens and Malamud, 2008]. Detection of hantavirus-specific secretory IgA is non-
47
48
49 19 invasive technique and has a promising future as a diagnostic tool. In addition, hantavirus-
50
51 20 specific secretory IgA could provide insight into the dynamics of hantavirus infection in
52
53
54 21 relation to the host immune response. Here, PUUV-specific salivary IgA was present in saliva
55
56 22 of infected patients and appearance of salivary IgA was associated with the disappearance of
57
58
59 23 the virus.
60

1
2
3 1
4
5
6 2**ACKNOWLEDGEMENTS**

3 Irene Eriksson is greatly acknowledged for her skilled technical assistance. This project was
4 supported by grants from the Kempe Foundation, The Swedish Heart-Lung Foundation, the
5 Swedish Society of Medical Microbiology, the County Councils of Northern Sweden, the
6 County Council of Västerbotten, and the Medical faculty of Umeå University.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 REFERENCES

- 2 Belec L, Legoff J, Si-Mohamed A, Bloch F, Mbopi Keou FX, Becquart P, Matta M, Prazuck T, Petite JP,
3 Gutmann L, Payan C. 2003. Mucosal humoral immune response to hepatitis C virus E1/E2
4 surface glycoproteins and HCV shedding in saliva and cervicovaginal fluids from chronically
5 HCV-infected patients. *J Hepatol* 38:833-842.
- 6 Biesbrock AR, Reddy MS, Levine MJ. 1991. Interaction of a salivary mucin-secretory immunoglobulin
7 A complex with mucosal pathogens. *Infect Immun* 59:3492-3497.
- 8 Botten J, Mirowsky K, Kusewitt D, Bharadwaj M, Yee J, Ricci R, Feddersen RM, Hjelle B. 2000.
9 Experimental infection model for Sin Nombre hantavirus in the deer mouse (*Peromyscus*
10 *maniculatus*). *Proc Natl Acad Sci U S A* 97:10578-10583.
- 11 Brandtzaeg P. 2007. Do salivary antibodies reliably reflect both mucosal and systemic immunity? *Ann*
12 *N Y Acad Sci* 1098:288-311.
- 13 Compton SR, Jacoby RO, Paturzo FX, Smith AL. 2004. Persistent Seoul virus infection in Lewis rats.
14 *Arch Virol* 149:1325-1339.
- 15 Corstjens P, Malamud D. 2008. Point-of-care diagnostics for infectious diseases. In: Wong D, editor.
16 *Salivary Diagnostics*. Ames, Iowa, USA: Wiley-Blackwell. p 140-143.
- 17 de Carvalho Nicacio C, Lundkvist A, Sjolander KB, Plyusnin A, Salonen EM, Bjorling E. 2000. A
18 neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. *J Med*
19 *Viro* 60:446-454.
- 20 Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barass C, Piconi S, Trabattoni D, Bwayo JJ,
21 Plummer F, Clerici M, Broliden K. 2002. Cross-clade HIV-1-specific neutralizing IgA in mucosal
22 and systemic compartments of HIV-1-exposed, persistently seronegative subjects. *J Acquir*
23 *Immune Defic Syndr* 30:413-420.

- 1
2
3 1 Douron E, Moriniere B, Matheron S, Girard PM, Gonzalez JP, Hirsch F, McCormick JB. 1984. HFRS
4
5 2 after a wild rodent bite in the Haute-Savoie--and risk of exposure to Hantaan-like virus in a
6
7 3 Paris laboratory. *Lancet* 1:676-677.
8
9
10 4 Elgh F, Linderholm M, Wadell G, Tarnvik A, Juto P. 1998. Development of humoral cross-reactivity to
11
12 5 the nucleocapsid protein of heterologous hantaviruses in nephropathia epidemica. *FEMS*
13
14 6 *Immunol Med Microbiol* 22:309-315.
15
16
17 7 Evander M, Eriksson I, Pettersson L, Juto P, Ahlm C, Olsson GE, Bucht G, Allard A. 2007. Puumala
18
19 8 hantavirus viremia diagnosed by real-time reverse transcriptase PCR using samples from
20
21 9 patients with hemorrhagic fever and renal syndrome. *J Clin Microbiol* 45:2491-2497.
22
23
24 10 Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, Hjelle B, Delgado I, Lee SJ, Mertz GJ. 2007.
25
26 11 Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary
27
28 12 syndrome in Chile. *J Infect Dis* 195:1563-1571.
29
30
31 13 Fox PC, Wolff A, Yeh CK, Atkinson JC, Baum BJ. 1988. Saliva inhibits HIV-1 infectivity. *J Am Dent Assoc*
32
33 14 116:635-637.
34
35
36 15 Groen J, Gerding M, Jordans JG, Clement JP, Osterhaus AD. 1994. Class and subclass distribution of
37
38 16 Hantavirus-specific serum antibodies at different times after the onset of nephropathia
39
40 17 epidemica. *J Med Virol* 43:39-43.
41
42
43 18 Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D. 2006. The role of crude human saliva and purified
44
45 19 salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1
46
47 20 in an inhibition assay. *Virol J* 3:99.
48
49
50 21 Hardestam J, Karlsson M, Falk KI, Olsson G, Klingstrom J, Lundkvist A. 2008a. Puumala hantavirus
51
52 22 excretion kinetics in bank voles (*Myodes glareolus*). *Emerg Infect Dis* 14:1209-1215.
53
54
55 23 Hardestam J, Lundkvist A, Klingstrom J. 2009. Sensitivity of Andes hantavirus to antiviral effect of
56
57 24 human saliva. *Emerg Infect Dis* 15:1140-1142.
58
59
60

- 1
2
3 1 Hardestam J, Petterson L, Ahlm C, Evander M, Lundkvist A, Klingstrom J. 2008b. Antiviral effect of
4
5 2 human saliva against hantavirus. *J Med Virol* 80:2122-2126.
6
7
8 3 Hartshorn KL, Ligtenberg A, White MR, Van Eijk M, Hartshorn M, Pemberton L, Holmskov U, Crouch
9
10 4 E. 2006. Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have
11
12 5 broad anti-influenza activities and interactions with surfactant protein D that vary according
13
14 6 to donor source and sialylation. *Biochem J* 393:545-553.
15
16
17 7 Hocini H, Belec L, Iscaki S, Garin B, Pillot J, Becquart P, Bomsel M. 1997. High-level ability of secretory
18
19 8 IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to
20
21 9 glycoprotein 160. *AIDS Res Hum Retroviruses* 13:1179-1185.
22
23
24 10 Johansson P, Olsson M, Lindgren L, Ahlm C, Elgh F, Holmstrom A, Bucht G. 2004. Complete gene
25
26 11 sequence of a human Puumala hantavirus isolate, Puumala Umea/hu: sequence comparison
27
28 12 and characterisation of encoded gene products. *Virus Res* 105:147-155.
29
30
31 13 Kanerva M, Paakkala A, Mustonen J, Paakkala T, Lahtela J, Pasternack A. 1996. Pulmonary
32
33 14 involvement in nephropathia epidemica: radiological findings and their clinical correlations.
34
35 15 *Clin Nephrol* 46:369-378.
36
37
38 16 Lee HW, Lee PW, Baek LJ, Song CK, Seong IW. 1981. Intraspecific transmission of Hantaan virus,
39
40 17 etiologic agent of Korean hemorrhagic fever, in the rodent *Apodemus agrarius*. *Am J Trop*
41
42 18 *Med Hyg* 30:1106-1112.
43
44
45 19 Ligtenberg AJ, Bikker FJ, De Blicck-Hogervorst JM, Veerman EC, Nieuw Amerongen AV. 2004. Binding
46
47 20 of salivary agglutinin to IgA. *Biochem J* 383:159-164.
48
49
50 21 Linderholm M, Bjermer L, Juto P, Roos G, Sandstrom T, Settergren B, Tarnvik A. 1993. Local host
51
52 22 response in the lower respiratory tract in nephropathia epidemica. *Scand J Infect Dis* 25:639-
53
54 23 646.
55
56
57
58
59
60

- 1
2
3 1 Linderholm M, Sandstrom T, Rinnstrom O, Groth S, Blomberg A, Tarnvik A. 1997. Impaired pulmonary
4
5 2 function in patients with hemorrhagic fever with renal syndrome. *Clin Infect Dis* 25:1084-
6
7 3 1089.
8
9
10 4 Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein MB, Lehner T. 1998. Characterization
11
12 5 of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in
13
14 6 humans. *Nat Med* 4:601-606.
15
16
17 7 Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula PJ. 2005. Person-to-person
18
19 8 transmission of Andes virus. *Emerg Infect Dis* 11:1848-1853.
20
21
22 9 Meisel H, Wolbert A, Razanskiene A, Marg A, Kazaks A, Sasnauskas K, Pauli G, Ulrich R, Kruger DH.
23
24 10 2006. Development of novel immunoglobulin G (IgG), IgA, and IgM enzyme immunoassays
25
26 11 based on recombinant Puumala and Dobrava hantavirus nucleocapsid proteins. *Clin Vaccine*
27
28 12 *Immunol* 13:1349-1357.
29
30
31 13 Moja P, Tranchat C, Tchou I, Pozzetto B, Lucht F, Desgranges C, Genin C. 2000. Neutralization of
32
33 14 human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected
34
35 15 patients. *J Infect Dis* 181:1607-1613.
36
37
38 16 Nugent CT, Dockter J, Bernardin F, Hecht R, Smith D, Delwart E, Pilcher C, Richman D, Busch M,
39
40 17 Giachetti C. 2009. Detection of HIV-1 in alternative specimen types using the APTIMA HIV-1
41
42 18 RNA Qualitative Assay. *J Virol Methods* 159:10-14.
43
44
45 19 Padula P, Figueroa R, Navarrete M, Pizarro E, Cadiz R, Bellomo C, Jofre C, Zaror L, Rodriguez E, Murua
46
47 20 R. 2004. Transmission study of Andes hantavirus infection in wild sigmodontine rodents. *J*
48
49 21 *Virol* 78:11972-11979.
50
51
52 22 Padula PJ, Rossi CM, Della Valle MO, Martinez PV, Colavecchia SB, Edelstein A, Miguel SD, Rabinovich
53
54 23 RD, Segura EL. 2000. Development and evaluation of a solid-phase enzyme immunoassay
55
56 24 based on Andes hantavirus recombinant nucleoprotein. *J Med Microbiol* 49:149-155.
57
58
59
60

- 1
2
3 1 Pettersson L, Klingstrom J, Hardestam J, Lundkvist A, Ahlm C, Evander M. 2008. Hantavirus RNA in
4
5 2 saliva from patients with hemorrhagic fever with renal syndrome. *Emerg Infect Dis* 14:406-
6
7 3 411.
8
9
10 4 Renegar KB, Small PA, Jr., Boykins LG, Wright PF. 2004. Role of IgA versus IgG in the control of
11
12 5 influenza viral infection in the murine respiratory tract. *J Immunol* 173:1978-1986.
13
14 6 Russel M. 2007. Mucosal immune defense: Immunoglobulin A. Kaetzel C, editor. N.Y.: Springer
15
16 7 Science. 144-172 p.
17
18 8 Saksida A, Duh D, Korva M, Avsic-Zupanc T. 2008. Dobrava virus RNA load in patients who have
19
20 9 hemorrhagic fever with renal syndrome. *J Infect Dis* 197:681-685.
21
22
23 10 St Jeor SC. 2004. Three-week incubation period for hantavirus infection. *Pediatr Infect Dis J* 23:974-
24
25 11 975.
26
27
28 12 Wickstrom C, Christersson C, Davies JR, Carlstedt I. 2000. Macromolecular organization of saliva:
29
30 13 identification of 'insoluble' MUC5B assemblies and non-mucin proteins in the gel phase.
31
32 14 *Biochem J* 351 Pt 2:421-428.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 FIGURE LEGENDS**
4

5
6 **2**

7
8 **3** Figure 1. Inverse association between presence of IgA antibodies and PUUV RNA in saliva
9
10 **4** samples ($P = 0.009$). Mean saliva PUUV RNA copy number was 30,960 copies/ml in patients
11
12 **5** without PUUV-specific salivary IgA and 2,046 copies/ml in patients with PUUV-specific
13
14 **6** salivary IgA.
15
16

17
18
19 **7** ° Outlier, * Extreme outlier
20
21

22
23 **8**
24
25

26 **9** Figure 2. PUUV nucleocapsid antigen in the parotid salivary gland of an HFRS patient. Using
27
28 **10** PUUV nucleocapsid protein specific monoclonal antibody and immunohistochemistry
29
30 **11** technique, viral antigen was demonstrated within the capillary endothelium of the organ.
31
32 **12** Specific punctuate granular staining within the capillary endothelial walls are indicated.
33
34
35

36
37 **13**
38
39

40 **14**
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Table 1. PUUV-specific IgA and RNA in HFRS patients.

Patient no.	Day of saliva collection (after disease onset)	PUUV IgA in saliva ^a	PUUV RNA (copies/ml) in saliva	Day of plasma collection (after disease onset)	PUUV RNA (copies/ml) in plasma
1	7	++	0	6	81,330
2	10	++	0	8	0
3	12	++	0	12	5,027
4	9	++	0	8	0
5	6	++	8,810	8	43,013
	10	++	0	11	3,145
6	25	++	0	27	0
	32	++	0	32	0
	52	-	0	52	0
7	10	+	0	10	0
8	7	+	0	7	9,721
	9	-	0	9	0
	11	-	0	11	0
9	9	+	9,582	10	3,724
10	5	+	2,589	5	36,231
11	5	+	1,530	8	3,044
12	7	-	31,284	7	73,291
	9	+	8,142	9	11,809
	11	+	0	11	5,142
13	3	-	pos ^b	3	pos ^b
14	6	-	43,095	6	26,756
15	11	-	57,965	11	64,809
	15	-	14,090	15	0
16	12	-	0	12	0
17	5	-	23,130	7	26,842
18	5	-	100,800	5	48,741
19	9	-	15,195	9	110,454
	11	-	0	11	39,176
	13	-	0	13	17,517
	20	-	0	20	1,801
20	3	-	0	3	149,903
	14	-	0	14	0
21	8	-	83,100	8	20,516
22	9	-	32,594	9	31,411
23	17	-	0	16	0
24	6	-	121,323	5	959,294
25	2	-	66,994	2	117,562
26	5	-	44,898	7	40,427
27	6	-	17,516	5	1,381,413
28	5	-	6,372	5	26,626
29	7	-	3,745	7	189,233
30	5	-	2,163	4	54,315
31	6	-	0	6	1,952
32	6	-	0	7	5,215
33	2	-	0	3	41,271

1
2
3
4
5
6 ^a IgA was diluted 1:10 and scored as negative (-), strongly positive (++) or weakly positive (+) by IF.
7

8 ^b PUUV-specific PCR on patient 13 was only performed by conventional PCR and scored as positive
9
10 (pos) or negative.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review




Inverse association between presence of IgA antibodies and PUUV RNA in saliva samples ($P = 0.009$). Mean saliva PUUV RNA copy number was 30,960 copies/ml in patients without PUUV-specific salivary IgA and 2,046 copies/ml in patients with PUUV-specific salivary IgA.

° Outlier, * Extreme outlier

166x130mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PUUV nucleocapsid antigen in the parotid salivary gland of an HFRS patient. Using PUUV nucleocapsid protein specific monoclonal antibody and immunohistochemistry technique, viral antigen was demonstrated within the capillary endothelium of the organ. Specific punctuate granular staining within the capillary endothelial walls are indicated.
215x159mm (300 x 300 DPI)